Abstract
Semicarbazones are synthesized by the condensation of semicarbazide and aldehyde/ketone. The literature survey revealed that semicarbazones had been emerged as compounds with diverse biological activities including anticonvulsant, antitubercular, anticancer, and antimicrobial activities. The anticonvulsant activity of semicarbazones is mainly attributed due to the presence of an aryl binding site with aryl/alkyl hydrophobic group, a hydrogen bonding domain and an electron donor group and they are suggested to act by inhibiting sodium ion (Na+) channel. Dimmock et al., reported an extensive series of semicarbazones and reported 4-(4-fluorophenoxy) benzaldehyde semicarbazone (C0102862, V102862) as lead molecule. In MES (oral) screening C0102862 showed protective index (PI > 315) more than carbamazepine (PI 101), phenytoin (PI > 21.6) and valproate (PI > 2.17). This review briefly describes the information available about semicarbazone analogs and their anticonvulsant activity.
Keywords: Anticonvulsant Agents, Binding site theory, Na+ channel blocker, Pharmacophore model, Review, Semicarbazones.
Central Nervous System Agents in Medicinal Chemistry
Title:Semicarbazone Analogs as Anticonvulsant Agents: A Review
Volume: 13 Issue: 2
Author(s): Mohamed Jawed Ahsan
Affiliation:
Keywords: Anticonvulsant Agents, Binding site theory, Na+ channel blocker, Pharmacophore model, Review, Semicarbazones.
Abstract: Semicarbazones are synthesized by the condensation of semicarbazide and aldehyde/ketone. The literature survey revealed that semicarbazones had been emerged as compounds with diverse biological activities including anticonvulsant, antitubercular, anticancer, and antimicrobial activities. The anticonvulsant activity of semicarbazones is mainly attributed due to the presence of an aryl binding site with aryl/alkyl hydrophobic group, a hydrogen bonding domain and an electron donor group and they are suggested to act by inhibiting sodium ion (Na+) channel. Dimmock et al., reported an extensive series of semicarbazones and reported 4-(4-fluorophenoxy) benzaldehyde semicarbazone (C0102862, V102862) as lead molecule. In MES (oral) screening C0102862 showed protective index (PI > 315) more than carbamazepine (PI 101), phenytoin (PI > 21.6) and valproate (PI > 2.17). This review briefly describes the information available about semicarbazone analogs and their anticonvulsant activity.
Export Options
About this article
Cite this article as:
Ahsan Jawed Mohamed, Semicarbazone Analogs as Anticonvulsant Agents: A Review, Central Nervous System Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/18715249113136660016
DOI https://dx.doi.org/10.2174/18715249113136660016 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ultrasonic Assisted Synthesis, Biological Evaluation, and Molecular Docking
of Chalcone-based 1,5-benzodiazepine as Potential Anticonvulsant
Agents
Current Enzyme Inhibition Synthesis, Neurotoxicity and Anticonvulsant Study of Some Benzothiazole Analogs
Letters in Drug Design & Discovery Pathogens and Chronic or Long-Term Neurologic Disorders
Cardiovascular & Hematological Disorders-Drug Targets Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission
Current Pharmaceutical Design Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Possible Protecting Role of TNF-α in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NFκB Signaling Pathway
Current Alzheimer Research Focusing on the Interactions between the GABAergic System and Neurosteroids in Neurodevelopmental Disorders
Current Pharmaceutical Design Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Inhibitors of Mammalian Central Nervous System Selective Amino Acid Transporters
Current Medicinal Chemistry subject Index To Volume 2
Current Genomics Epilepsy, Theories and Treatment Inside Corpus Hippocraticum
Current Pharmaceutical Design Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics Recent Inventions in Powder Technology and Granular Science Incorporating Improved Drug Delivery
Recent Patents on Engineering Retraction Notice: Potential Application of Venom Proteins in Designing of Medicines for Treating Human Neurodegenerative Disorders
Protein & Peptide Letters Animal Peptides Targeting Voltage-Activated Sodium Channels
Current Pharmaceutical Design